Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT

Naoya Oishi, Kazuo Hashikawa, Hidefumi Yoshida, Koichi Ishizu, Masashi Ueda, Hidekazu Kawashima, Hideo Saji, Hidenao Fukuyama

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We quantified in vivo brain nicotinic acetylcholine receptor (nAChR) distributions in patients with Parkinson's disease (PD) and evaluated correlations between nAChR distributions and clinical variables of the patients, especially dopaminergic medications. Ten patients with PD without dementia underwent 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine (123I-5IA) single photon emission computed tomography (SPECT) and the data were compared with those of 10 age-matched healthy volunteers. Correlation analyses between 123I-5IA distribution volumes (DVs) in each brain region and clinical variables of the patients were also performed. The PD group showed a statistically significant decrease (20-25%) in the brainstem and frontal cortex as compared with the control group. Although age, duration of disease, daily dose of levodopa, duration of PD medication use, and scores on the motor section of Unified Parkinson's Disease Rating Scale were not significantly correlated with DV values in any brain regions, high daily doses of dopamine agonist showed a significant negative correlation with DVs in the cerebellum, and temporal, parietal and occipital cortices. These findings suggest that patients with PD without dementia can show reductions especially in the brainstem and frontal cortex. They also suggest that dopamine agonists can have a negative influence on the distribution of nAChRs.

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalJournal of the Neurological Sciences
Volume256
Issue number1-2
DOIs
Publication statusPublished - May 15 2007
Externally publishedYes

Fingerprint

Nicotinic Receptors
Single-Photon Emission-Computed Tomography
Parkinson Disease
Dopamine Agonists
Frontal Lobe
Brain Stem
Dementia
Brain
Hospital Distribution Systems
Occipital Lobe
Parietal Lobe
Levodopa
Temporal Lobe
Cerebellum
Healthy Volunteers
Control Groups

Keywords

  • 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine
  • Distribution volume
  • Dopamine agonist
  • Nicotinic acetylcholine receptors
  • Parkinson's disease
  • Single photon emission computed tomography

ASJC Scopus subject areas

  • Ageing
  • Clinical Neurology
  • Surgery
  • Developmental Neuroscience
  • Neurology
  • Neuroscience(all)

Cite this

Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT. / Oishi, Naoya; Hashikawa, Kazuo; Yoshida, Hidefumi; Ishizu, Koichi; Ueda, Masashi; Kawashima, Hidekazu; Saji, Hideo; Fukuyama, Hidenao.

In: Journal of the Neurological Sciences, Vol. 256, No. 1-2, 15.05.2007, p. 52-60.

Research output: Contribution to journalArticle

Oishi, N, Hashikawa, K, Yoshida, H, Ishizu, K, Ueda, M, Kawashima, H, Saji, H & Fukuyama, H 2007, 'Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT', Journal of the Neurological Sciences, vol. 256, no. 1-2, pp. 52-60. https://doi.org/10.1016/j.jns.2007.02.014
Oishi, Naoya ; Hashikawa, Kazuo ; Yoshida, Hidefumi ; Ishizu, Koichi ; Ueda, Masashi ; Kawashima, Hidekazu ; Saji, Hideo ; Fukuyama, Hidenao. / Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT. In: Journal of the Neurological Sciences. 2007 ; Vol. 256, No. 1-2. pp. 52-60.
@article{3ebe7858f8cf4bfd93645c5db40e7e6a,
title = "Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT",
abstract = "We quantified in vivo brain nicotinic acetylcholine receptor (nAChR) distributions in patients with Parkinson's disease (PD) and evaluated correlations between nAChR distributions and clinical variables of the patients, especially dopaminergic medications. Ten patients with PD without dementia underwent 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine (123I-5IA) single photon emission computed tomography (SPECT) and the data were compared with those of 10 age-matched healthy volunteers. Correlation analyses between 123I-5IA distribution volumes (DVs) in each brain region and clinical variables of the patients were also performed. The PD group showed a statistically significant decrease (20-25{\%}) in the brainstem and frontal cortex as compared with the control group. Although age, duration of disease, daily dose of levodopa, duration of PD medication use, and scores on the motor section of Unified Parkinson's Disease Rating Scale were not significantly correlated with DV values in any brain regions, high daily doses of dopamine agonist showed a significant negative correlation with DVs in the cerebellum, and temporal, parietal and occipital cortices. These findings suggest that patients with PD without dementia can show reductions especially in the brainstem and frontal cortex. They also suggest that dopamine agonists can have a negative influence on the distribution of nAChRs.",
keywords = "5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine, Distribution volume, Dopamine agonist, Nicotinic acetylcholine receptors, Parkinson's disease, Single photon emission computed tomography",
author = "Naoya Oishi and Kazuo Hashikawa and Hidefumi Yoshida and Koichi Ishizu and Masashi Ueda and Hidekazu Kawashima and Hideo Saji and Hidenao Fukuyama",
year = "2007",
month = "5",
day = "15",
doi = "10.1016/j.jns.2007.02.014",
language = "English",
volume = "256",
pages = "52--60",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Quantification of nicotinic acetylcholine receptors in Parkinson's disease with 123I-5IA SPECT

AU - Oishi, Naoya

AU - Hashikawa, Kazuo

AU - Yoshida, Hidefumi

AU - Ishizu, Koichi

AU - Ueda, Masashi

AU - Kawashima, Hidekazu

AU - Saji, Hideo

AU - Fukuyama, Hidenao

PY - 2007/5/15

Y1 - 2007/5/15

N2 - We quantified in vivo brain nicotinic acetylcholine receptor (nAChR) distributions in patients with Parkinson's disease (PD) and evaluated correlations between nAChR distributions and clinical variables of the patients, especially dopaminergic medications. Ten patients with PD without dementia underwent 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine (123I-5IA) single photon emission computed tomography (SPECT) and the data were compared with those of 10 age-matched healthy volunteers. Correlation analyses between 123I-5IA distribution volumes (DVs) in each brain region and clinical variables of the patients were also performed. The PD group showed a statistically significant decrease (20-25%) in the brainstem and frontal cortex as compared with the control group. Although age, duration of disease, daily dose of levodopa, duration of PD medication use, and scores on the motor section of Unified Parkinson's Disease Rating Scale were not significantly correlated with DV values in any brain regions, high daily doses of dopamine agonist showed a significant negative correlation with DVs in the cerebellum, and temporal, parietal and occipital cortices. These findings suggest that patients with PD without dementia can show reductions especially in the brainstem and frontal cortex. They also suggest that dopamine agonists can have a negative influence on the distribution of nAChRs.

AB - We quantified in vivo brain nicotinic acetylcholine receptor (nAChR) distributions in patients with Parkinson's disease (PD) and evaluated correlations between nAChR distributions and clinical variables of the patients, especially dopaminergic medications. Ten patients with PD without dementia underwent 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine (123I-5IA) single photon emission computed tomography (SPECT) and the data were compared with those of 10 age-matched healthy volunteers. Correlation analyses between 123I-5IA distribution volumes (DVs) in each brain region and clinical variables of the patients were also performed. The PD group showed a statistically significant decrease (20-25%) in the brainstem and frontal cortex as compared with the control group. Although age, duration of disease, daily dose of levodopa, duration of PD medication use, and scores on the motor section of Unified Parkinson's Disease Rating Scale were not significantly correlated with DV values in any brain regions, high daily doses of dopamine agonist showed a significant negative correlation with DVs in the cerebellum, and temporal, parietal and occipital cortices. These findings suggest that patients with PD without dementia can show reductions especially in the brainstem and frontal cortex. They also suggest that dopamine agonists can have a negative influence on the distribution of nAChRs.

KW - 5-123I-iodo-3-(2(S)-azetidinylmethoxy)pyridine

KW - Distribution volume

KW - Dopamine agonist

KW - Nicotinic acetylcholine receptors

KW - Parkinson's disease

KW - Single photon emission computed tomography

UR - http://www.scopus.com/inward/record.url?scp=34147108303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147108303&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2007.02.014

DO - 10.1016/j.jns.2007.02.014

M3 - Article

C2 - 17367812

AN - SCOPUS:34147108303

VL - 256

SP - 52

EP - 60

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -